Articles By Jack Cush, MD
Pre-Clinical Use of Rituximab Forestalls Rheumatoid Onset
The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
Read Article
Hospitalizations Decline for Rheumatoid Arthritis, But Increase in Gout
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
Read Article
EULAR: Tofacitinib Effective in Ankylosing Spondylitis
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
Read Article
GiACTA Study Shows Benefit of Adding Tocilizumab to Steroid Taper in Giant Cell Arteritis
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
Read Article
Eight Deaths Linked to Methotrexate in Australia
Methotrexate , a cornerstone drug used to treat rheumatoid arthritis, has led to 90 hospitalizations and 7 deaths according to a recent report from the Medical Journal of Australia.
Read Article
Comorbidities Seen with ANCA-Associated Vasculitis
The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.
Read Article
April-May 2016 Top Social Media News
In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.
Read Article
RheumNow Week in Review - 3 June 2016
This week's highlights from RheumNow.com include:
Read Article
Patient Reluctance to Take Bisphosphonates
The NY Times reports that millions of Americans with osteoporosis are driven to stop or not take bisphosphonate therapies over the fear of exceedingly rare side effects - osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read Article
Morning Stiffness Madness
Rheumatologists distinguish themselves from their medical colleagues in several ways: exceptional joint exam and joint injection skills, interpretation of complex immunologic findings and cost-efficient ways of managing common musculoskeletal disorders. But what’s the one trait, skill or question that defines the acumen of the rheumatologist? Please don’t say morning stiffness.
Read Article
